ZymoGenetics, Inc.
ZymoGenetics Collaboration with Bristol-Myers Squibb Clears Review Under Hart-Scott-Rodino Antitrust Improvements Act
Published in Genetics and Environmental Law Weekly, March 21st, 2009
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced United States Federal Trade Commission and Department of Justice clearance under provisions of the Hart-Scott-Rodino Antitrust Improvements Act for the previously announced global collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for PEG-Interferon lambda. The collaboration agreement became effective upon clearance, and ZymoGenetics will receive payment of an $85.0 million licensing fee.
PEG-Interferon lambda (IL-29) is a novel type 3 interferon currently in Phase 1b development for Hepatitis C. The native human protein Interferon lambda is generated by the immune system in response to viral infection. PEG-Interferon...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
More Articles from Genetics and Environmental Law Weekly
- Inspire Pharmaceuticals, Inc.
Inspire Reports Fourth Quarter and Full Year 2008 Financial Results - Luminex Corporation
Luminex Unveils Keynote Speakers for Planet xMAP USA 2009 - PDI, Inc. and Sequenom Center for Molecular Medicine, LLC
Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests - Acute Myeloid Leukemia
Research in the area of acute myeloid leukemia reported from T.A. Fehniger and colleagues - Aging
New aging study findings recently were published by W. Chatoo and co-researchers - Aging
Research results from University of Alabama, Department of Biology update knowledge of aging - More from this issue of Genetics and Environmental Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
